Alpha Cognition (ACOG) Stock Overview
A biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACOG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alpha Cognition Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.06 |
| 52 Week High | US$12.63 |
| 52 Week Low | US$3.75 |
| Beta | 2.71 |
| 1 Month Change | -13.15% |
| 3 Month Change | -13.61% |
| 1 Year Change | -21.37% |
| 3 Year Change | -35.76% |
| 5 Year Change | n/a |
| Change since IPO | -57.01% |
Recent News & Updates
Shareholder Returns
| ACOG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | -1.7% | 2.3% |
| 1Y | -21.4% | -9.8% | 17.2% |
Return vs Industry: ACOG underperformed the US Biotechs industry which returned -9.8% over the past year.
Return vs Market: ACOG underperformed the US Market which returned 17.2% over the past year.
Price Volatility
| ACOG volatility | |
|---|---|
| ACOG Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ACOG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACOG's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Michael McFadden | www.alphacognition.com |
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.
Alpha Cognition Inc. Fundamentals Summary
| ACOG fundamental statistics | |
|---|---|
| Market cap | US$130.26m |
| Earnings (TTM) | -US$20.01m |
| Revenue (TTM) | US$4.59m |
Is ACOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACOG income statement (TTM) | |
|---|---|
| Revenue | US$4.59m |
| Cost of Revenue | US$1.37m |
| Gross Profit | US$3.22m |
| Other Expenses | US$23.23m |
| Earnings | -US$20.01m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | 70.11% |
| Net Profit Margin | -436.39% |
| Debt/Equity Ratio | 0% |
How did ACOG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/29 12:52 |
| End of Day Share Price | 2025/08/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alpha Cognition Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Chelsea Stellick | iA Capital Markets |
| David Joseph Storms | Stonegate Capital Partners, Inc. |